Evaluation of ubiquitin C-terminal hydrolase-L1 enzyme levels in patients with epilepsy

ABSTRACT Objective: Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) enzyme levels were investigated in patients with epilepsy, epileptic seizure, remission period, and healthy individuals. Methods: Three main groups were evaluated, including epileptic seizure, patients with epilepsy in the non-seizure period, and healthy volunteers. The patients having a seizure in the Emergency department or brought by a postictal confusion were included in the epileptic attack group. The patients having a seizure attack or presenting to the Neurology outpatient department for follow up were included in the non-seizure (remission period) group. Results: The UCH-L1 enzyme levels of 160 patients with epilepsy (80 patients with epileptic attack and 80 patients with epilepsy in the non-seizure period) and 100 healthy volunteers were compared. Whereas the UCH-L1 enzyme levels were 8.30 (IQR=6.57‒11.40) ng/mL in all patients with epilepsy, they were detected as 3.90 (IQR=3.31‒7.22) ng/mL in healthy volunteers, and significantly increased in numbers for those with epilepsy (p<0.001). However, whereas the UCH-L1 levels were 8.50 (IQR=6.93‒11.16) ng/mL in the patients with epileptic seizures, they were 8.10 (IQR=6.22‒11.93) ng/mL in the non-seizure period, and no significant difference was detected (p=0.6123). When the UCH-L1 cut-off value was taken as 4.34 mg/mL in Receiver Operating Characteristic (ROC) Curve analysis, the sensitivity and specificity detected were 93.75 and 66.00%, respectively (AUG=0.801; p<0.0001; 95%CI 0.747‒0.848) for patients with epilepsy. Conclusion: Even though UCH-L1 levels significantly increased more in patients with epilepsy than in healthy individuals, there was no difference between epileptic seizure and non-seizure periods.

Saved in:
Bibliographic Details
Main Authors: YASAK,Ibrahim Halil, YILMAZ,Mustafa, GÖNEN,Murat, ATESCELIK,Metin, GURGER,Mehtap, ILHAN,Nevin, GOKTEKIN,Mehmet Cagri
Format: Digital revista
Language:English
Published: Academia Brasileira de Neurologia - ABNEURO 2020
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000700424
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0004-282X2020000700424
record_format ojs
spelling oai:scielo:S0004-282X20200007004242020-07-29Evaluation of ubiquitin C-terminal hydrolase-L1 enzyme levels in patients with epilepsyYASAK,Ibrahim HalilYILMAZ,MustafaGÖNEN,MuratATESCELIK,MetinGURGER,MehtapILHAN,NevinGOKTEKIN,Mehmet Cagri Epilepsy Ubiquitin Seizures ABSTRACT Objective: Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) enzyme levels were investigated in patients with epilepsy, epileptic seizure, remission period, and healthy individuals. Methods: Three main groups were evaluated, including epileptic seizure, patients with epilepsy in the non-seizure period, and healthy volunteers. The patients having a seizure in the Emergency department or brought by a postictal confusion were included in the epileptic attack group. The patients having a seizure attack or presenting to the Neurology outpatient department for follow up were included in the non-seizure (remission period) group. Results: The UCH-L1 enzyme levels of 160 patients with epilepsy (80 patients with epileptic attack and 80 patients with epilepsy in the non-seizure period) and 100 healthy volunteers were compared. Whereas the UCH-L1 enzyme levels were 8.30 (IQR=6.57‒11.40) ng/mL in all patients with epilepsy, they were detected as 3.90 (IQR=3.31‒7.22) ng/mL in healthy volunteers, and significantly increased in numbers for those with epilepsy (p<0.001). However, whereas the UCH-L1 levels were 8.50 (IQR=6.93‒11.16) ng/mL in the patients with epileptic seizures, they were 8.10 (IQR=6.22‒11.93) ng/mL in the non-seizure period, and no significant difference was detected (p=0.6123). When the UCH-L1 cut-off value was taken as 4.34 mg/mL in Receiver Operating Characteristic (ROC) Curve analysis, the sensitivity and specificity detected were 93.75 and 66.00%, respectively (AUG=0.801; p<0.0001; 95%CI 0.747‒0.848) for patients with epilepsy. Conclusion: Even though UCH-L1 levels significantly increased more in patients with epilepsy than in healthy individuals, there was no difference between epileptic seizure and non-seizure periods.info:eu-repo/semantics/openAccessAcademia Brasileira de Neurologia - ABNEUROArquivos de Neuro-Psiquiatria v.78 n.7 20202020-07-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000700424en10.1590/0004-282x20200040
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author YASAK,Ibrahim Halil
YILMAZ,Mustafa
GÖNEN,Murat
ATESCELIK,Metin
GURGER,Mehtap
ILHAN,Nevin
GOKTEKIN,Mehmet Cagri
spellingShingle YASAK,Ibrahim Halil
YILMAZ,Mustafa
GÖNEN,Murat
ATESCELIK,Metin
GURGER,Mehtap
ILHAN,Nevin
GOKTEKIN,Mehmet Cagri
Evaluation of ubiquitin C-terminal hydrolase-L1 enzyme levels in patients with epilepsy
author_facet YASAK,Ibrahim Halil
YILMAZ,Mustafa
GÖNEN,Murat
ATESCELIK,Metin
GURGER,Mehtap
ILHAN,Nevin
GOKTEKIN,Mehmet Cagri
author_sort YASAK,Ibrahim Halil
title Evaluation of ubiquitin C-terminal hydrolase-L1 enzyme levels in patients with epilepsy
title_short Evaluation of ubiquitin C-terminal hydrolase-L1 enzyme levels in patients with epilepsy
title_full Evaluation of ubiquitin C-terminal hydrolase-L1 enzyme levels in patients with epilepsy
title_fullStr Evaluation of ubiquitin C-terminal hydrolase-L1 enzyme levels in patients with epilepsy
title_full_unstemmed Evaluation of ubiquitin C-terminal hydrolase-L1 enzyme levels in patients with epilepsy
title_sort evaluation of ubiquitin c-terminal hydrolase-l1 enzyme levels in patients with epilepsy
description ABSTRACT Objective: Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) enzyme levels were investigated in patients with epilepsy, epileptic seizure, remission period, and healthy individuals. Methods: Three main groups were evaluated, including epileptic seizure, patients with epilepsy in the non-seizure period, and healthy volunteers. The patients having a seizure in the Emergency department or brought by a postictal confusion were included in the epileptic attack group. The patients having a seizure attack or presenting to the Neurology outpatient department for follow up were included in the non-seizure (remission period) group. Results: The UCH-L1 enzyme levels of 160 patients with epilepsy (80 patients with epileptic attack and 80 patients with epilepsy in the non-seizure period) and 100 healthy volunteers were compared. Whereas the UCH-L1 enzyme levels were 8.30 (IQR=6.57‒11.40) ng/mL in all patients with epilepsy, they were detected as 3.90 (IQR=3.31‒7.22) ng/mL in healthy volunteers, and significantly increased in numbers for those with epilepsy (p<0.001). However, whereas the UCH-L1 levels were 8.50 (IQR=6.93‒11.16) ng/mL in the patients with epileptic seizures, they were 8.10 (IQR=6.22‒11.93) ng/mL in the non-seizure period, and no significant difference was detected (p=0.6123). When the UCH-L1 cut-off value was taken as 4.34 mg/mL in Receiver Operating Characteristic (ROC) Curve analysis, the sensitivity and specificity detected were 93.75 and 66.00%, respectively (AUG=0.801; p<0.0001; 95%CI 0.747‒0.848) for patients with epilepsy. Conclusion: Even though UCH-L1 levels significantly increased more in patients with epilepsy than in healthy individuals, there was no difference between epileptic seizure and non-seizure periods.
publisher Academia Brasileira de Neurologia - ABNEURO
publishDate 2020
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000700424
work_keys_str_mv AT yasakibrahimhalil evaluationofubiquitincterminalhydrolasel1enzymelevelsinpatientswithepilepsy
AT yilmazmustafa evaluationofubiquitincterminalhydrolasel1enzymelevelsinpatientswithepilepsy
AT gonenmurat evaluationofubiquitincterminalhydrolasel1enzymelevelsinpatientswithepilepsy
AT atescelikmetin evaluationofubiquitincterminalhydrolasel1enzymelevelsinpatientswithepilepsy
AT gurgermehtap evaluationofubiquitincterminalhydrolasel1enzymelevelsinpatientswithepilepsy
AT ilhannevin evaluationofubiquitincterminalhydrolasel1enzymelevelsinpatientswithepilepsy
AT goktekinmehmetcagri evaluationofubiquitincterminalhydrolasel1enzymelevelsinpatientswithepilepsy
_version_ 1756374799405285376